Cantor Fitzgerald, L. P. X4 Pharmaceuticals, Inc Transaction History
Cantor Fitzgerald, L. P.
- $2.48 Billion
- Q4 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 40,251 shares of XFOR stock, worth $11,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,251Holding current value
$11,270% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XFOR
# of Institutions
98Shares Held
99.6MCall Options Held
421KPut Options Held
80.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$4.74 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$4.2 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$2.99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$2.3 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$2.05 Million2.9% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $19.2M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...